Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel

Yair Goldberg, Micha Mandel, Yonatan Woodbridge, Ronen Fluss, Ilya Novikov, Rami Yaari, Arnona Ziv, Laurence Freedman, Amit Huppert
doi: https://doi.org/10.1101/2021.04.20.21255670

Article Information

doi 
https://doi.org/10.1101/2021.04.20.21255670
History 
  • April 24, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Yair Goldberg□,1,*,
  2. Micha Mandel□,2,
  3. Yonatan Woodbridge3,
  4. Ronen Fluss3,
  5. Ilya Novikov3,
  6. Rami Yaari3,
  7. Arnona Ziv3,
  8. Laurence Freedman3 and
  9. Amit Huppert3,4
  1. 1Technion - Israel Institute of Technology, Israel
  2. 2The Hebrew University of Jerusalem, Israel
  3. 3The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Israel
  4. 4Tel Aviv University, Israel
  1. ↵*corresponding author; email: yairgo{at}technion.ac.il

  1. ↵□ Contributed equally

Back to top
Posted April 24, 2021.
Download PDF
Data/Code
Email
Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel
Yair Goldberg, Micha Mandel, Yonatan Woodbridge, Ronen Fluss, Ilya Novikov, Rami Yaari, Arnona Ziv, Laurence Freedman, Amit Huppert
medRxiv 2021.04.20.21255670; doi: https://doi.org/10.1101/2021.04.20.21255670
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area